Skip to main content
EXEL logo

Exelixis, Inc. (EXEL) Stock: Price, Forecast & Analyst Target

Exelixis, Inc. (EXEL) — MoonshotScore 98/100 (Exceptional band), calculated Nov 18, 2026. Price $64.63 (-1.82%), as of the Nov 20, 2026 trading session; market cap $15.8B.

Educational signal · not a buy or sell recommendation · How to read this

$64.63 −$1.20 (-1.82%) Market Cap $15.8B

Exelixis, Inc. · EXEL · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Exelixis is an oncology drug developer with an established commercial franchise, not a biotechnology company waiting for its pipeline to produce meaningful revenue. The case rests on whether CABOMETYX can keep expanding product economics while research spending builds therapies capable of reducing dependence on cabozantinib.

Price as of Nov 20, 2026

Key Statistics

98 of 100

MoonshotScore v2 · Exelixis (EXEL)

Exceptional
Business Quality Elite (98)
Financial Safety Fortress (93)
Valuation Full (53)
Growth Durability Compounding (95)
Momentum Surging (94)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • Altman Z 17.86 · Piotroski F 6
  • ROE 44.3% · ROA 23.5% · current ratio 3.21

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for EXEL (58 recorded, newest six shown)
RecordedScoreBand
98Exceptional
98Exceptional
98Exceptional
98Exceptional
98Exceptional
98Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$64.63
Change on the day-1.82%
52-week range$39.71–$73.69
Market capitalisation$15.8B—
Price / earnings (trailing)19.86
Shares traded on the day2.04M
Beta (volatility vs the S&P 500)0.42

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $39, high $70, latest $65. $70 $39 high $70 Oct 17, 2025 Nov 20, 2026 · $65 $39Oct 17, 2025$39Oct 31, 2025$42Nov 14, 2025$44Nov 28, 2025$41Dec 12, 2025$46Dec 26, 2025$44Jan 9, 2026$44Jan 23, 2026$44Feb 6, 2026$44Feb 20, 2026$42Mar 6, 2026$41Mar 20, 2026$44Apr 2, 2026$45Apr 17, 2026$44May 1, 2026$50May 15, 2026$50May 29, 2026$53Jun 12, 2026$55Jun 26, 2026$57Jul 10, 2026$55Jul 24, 2026$54Aug 7, 2026$54Aug 21, 2026$59Sep 4, 2026$58Sep 18, 2026$58Oct 2, 2026$62Oct 16, 2026$69Oct 30, 2026$69Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Exelixis (EXEL): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Overvalued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Exelixis (EXEL), and what does it report?

Short answer · as of

Exelixis discovers, develops and markets cancer medicines, led by CABOMETYX and COMETRIQ, which share cabozantinib as their active compound.

Its portfolio also includes partnered products, while its development work spans kinase inhibitors and an antibody-drug conjugate for solid tumors and other cancers.

Reported revenue is not a pure royalty stream. Product sales supply the dominant contribution, supplemented by license and collaboration revenue, so changes in prescribing demand matter directly alongside milestones and partner economics.

2 · Latest results

What do the latest results show for Exelixis (EXEL)?

Revenue and gross profit continued to rise in the latest period, while operating profit eased despite the higher top line. Research and commercial spending increased, showing that incremental revenue did not flow through untouched, although net income remained strong and diluted earnings stayed well above earlier periods.

Recent earnings have generally exceeded expectations even when revenue has occasionally fallen short. That pattern points to expense control and high product gross margins as important contributors to earnings delivery, rather than revenue surprises alone.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$598M$194M$0.69 (diluted)
Dec 2025$599M$245M$0.88 (diluted)
Mar 2026$611M$210M$0.79 (diluted)
Jun 2026$629M$212M$0.82 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Exelixis (EXEL)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Exelixis combines sustained profitability with substantial operating cash generation and modest capital expenditure. Cash and investments comfortably exceed debt and total liabilities, giving the company room to fund development without relying on near-term external financing.

The balance sheet is stronger than the movement in cash and short-term investments alone suggests because a meaningful portion of liquidity sits in longer-term investments. Even so, the shorter-duration balance has declined across the reported window, so continued cash generation matters as research and commercial spending remain substantial.

The business risk is concentration: product revenue dominates, and the commercial portfolio is anchored by medicines derived from cabozantinib. A deterioration in that franchise could pressure revenue, profit and internally funded pipeline investment at the same time.

4 · What to check next?

What should you watch next at Exelixis (EXEL)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $2.56B · EPS 3.71 · 12 analysts.

Watch whether CABOMETYX-led product revenue keeps rising while operating profit resumes growth. The latest period paired a stronger top line with higher research and selling costs, making expense absorption as informative as headline revenue.

Operating cash flow should remain aligned with reported profit, and the mix between short-term cash and longer-term investments deserves attention when judging financial flexibility. Pipeline progress matters most where it can broaden the franchise beyond cabozantinib rather than merely add spending.

The scheduled earnings release carries expectations for further revenue and earnings growth. The useful comparison will be against the recent pattern of steady revenue expansion, resilient margins and earnings delivery that has often surpassed forecasts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Exelixis compare with its peers?

Short answer

Exelixis's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Exelixis differs from development-stage biotechnology companies because marketed oncology products already support profit, cash generation and ongoing research. It also differs from broadly diversified pharmaceutical groups: commercial exposure is concentrated around cabozantinib, while license and collaboration arrangements extend the portfolio and geographic reach.

That combination creates an unusual financial shape for biotechnology: very high gross margins, strong returns and low leverage alongside material research spending. The tradeoff is that current economics depend heavily on an established franchise while the pipeline carries the burden of diversification.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis (EXEL) — this page$64.63$15.8B98
United Therapeutics Corporation (UTHR) Same industry, near in market value$559.10 Nov 19, 2026$23.8B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$156.59 Nov 19, 2026$15.9B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$91.35 Nov 20, 2026$10.4B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.67 Nov 20, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$115.87 Nov 19, 2026$23.6B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$124.02 Nov 19, 2026$8.09B88 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$159.68 Nov 19, 2026$11.3B83 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$147.82 Nov 19, 2026$19.8B72 5-pillar Nov 18, 2026
Madrigal Pharmaceuticals, Inc. (MDGL) Named competitor$396.74 Nov 19, 2026$9.22B35 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$49.00 – $65.00
Consensus target
$54.20
Median target
$52.50
Revenue estimate
$2.56B
EPS estimate
$3.71

Consensus record · Captured .

Measured against a quoted price of $64.63 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Aug 10, 2026

Transactions
14
Identified insiders
11
Purchases
0
Sales
4
Other transactions
10

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EXEL in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.08%$19.19MTrimmed −18.0% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Exelixis (EXEL)?

Read these with our analysis →

EXEL Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

Why is CABOMETYX so important to Exelixis?

CABOMETYX is a marketed cabozantinib therapy and sits at the center of a product-led revenue base. Its commercial durability helps determine how much profit and cash Exelixis can direct toward pipeline development.

CABOMETYX and COMETRIQ are distinct marketed formulations derived from cabozantinib, a compound that inhibits several kinases involved in tumor biology. Their shared origin makes cabozantinib central to the current commercial portfolio.

Do license and collaboration payments drive Exelixis revenue?

Product sales are the dominant reported revenue source, while license and collaboration revenue provide additional contributions. Exelixis therefore has direct commercial exposure rather than relying mainly on partner payments.

Can Exelixis fund its oncology pipeline internally?

Strong operating cash flow, minimal capital needs and liquidity well above debt support internal research funding. Continued CABOMETYX-led cash generation remains important because research spending is substantial and the shorter-duration cash balance has declined across the reported window.

What is the EXEL stock price today?

The last price recorded for Exelixis, Inc. (EXEL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the EXEL price target?

The analyst consensus price target for Exelixis, Inc. (EXEL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 1. What is Exelixis (EXEL), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Exelixis (EXEL)?: Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Reported versus estimated, last 8 quarters; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Exelixis (EXEL)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Trailing twelve-month ratio set; Revenue by segment; Business description
  • 4. What should you watch next at Exelixis (EXEL)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and investment components; Cash and short-term investments over time (USD millions); Reported versus estimated, last 8 quarters; Next earnings report; Business description
  • 5. How does Exelixis compare with its peers?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Trailing twelve-month ratio set; Annual revenue and net result (USD millions)
  • FAQ: Why is CABOMETYX so important to Exelixis?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: How are CABOMETYX and COMETRIQ related?: Business description
  • FAQ: Do license and collaboration payments drive Exelixis revenue?: Revenue by segment; Business description
  • FAQ: Can Exelixis fund its oncology pipeline internally?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Quarterly income statement (USD thousands); Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold EXEL

Funds in our ETF coverage that list EXEL among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
ERShares Private-Public Crossover ETF (XOVR)3.23%